GlaxoSmithKline and Vir submit Covid-19 mAb for emergency authorization

GlaxoSmithKline and Vir submit Covid-19 mAb for emergency authorization

Source: 
Endpoints
snippet: 

As the US continues to monitor the impact of variants on authorized monoclonal antibodies (mAbs) and shake up which mAbs are distributed where, GlaxoSmithKline and Vir Biotechnology said Friday that they’re seeking an emergency use authorization for their own mAb.